Ultralow Dose PET Imaging for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using PET scans to spot and track cancer. The aim is to determine if a much lower dose of radiation can be used, making it safer for participants. Participants will receive an injection of a special tracer, 18F-FDG (a radioactive glucose compound), and undergo imaging to evaluate the effectiveness of this new method. Suitable candidates have cancer and can remain in a scanner for up to three hours. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to innovative cancer detection methods.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.
What prior data suggests that this ultralow dose PET imaging technique is safe for cancer detection?
Research has shown that ultralow dose 18F-FDG PET imaging is safe for humans. Some studies have even used it for cancer checks in pregnant women due to its low radiation levels. This method is generally well-tolerated and reduces risks. The radiation in this imaging is much lower than in standard procedures, making it a safer choice for many patients. Evidence indicates that it accurately detects cancer while keeping radiation exposure low. So far, these studies have reported no major side effects, supporting its safety.12345
Why are researchers excited about this trial?
Researchers are excited about ultralow dose 18F-FDG imaging for cancer because it offers a way to reduce radiation exposure during PET scans, which are commonly used to detect and monitor cancer. Unlike standard PET scans that use higher doses of radioactive tracers, this method uses a minimal amount of 18F-FDG, making it safer for patients, especially those requiring repeated imaging. Additionally, maintaining image quality with a lower dose could revolutionize cancer imaging by providing critical information while minimizing potential risks associated with radiation.
What evidence suggests that this ultralow dose PET imaging technique is effective for cancer detection and monitoring?
Research has shown that 18F-FDG PET imaging excels at detecting and monitoring cancer. Studies have found it more accurate than other methods, particularly in determining cancer stages or checking for recurrence, aiding doctors in choosing the best care for patients. In this trial, participants will join the Ultralow Dose 18F-FDG Imaging Group, which employs a new method that significantly reduces radioactive material, enhancing safety. One study found that radiation could be reduced by 90% without losing important image details. This advancement makes imaging safer for patients while still providing doctors with a clear understanding of the cancer.678910
Are You a Good Fit for This Trial?
This trial is for healthy individuals and cancer patients interested in a new PET scan technique that uses much less radiation. Specific eligibility criteria are not provided, so participants should inquire with the study team to determine if they qualify.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants are injected with a radioactive tracer called 18F-FDG and imaged on a high-sensitivity PET scanner for up to 3 hours
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 18F-FDG
Find a Clinic Near You
Who Is Running the Clinical Trial?
Akiva Mintz
Lead Sponsor